Bayer: exclusive licensing agreement with Cytokinetics in Japan

(CercleFinance.com) - Bayer announced Tuesday that it has signed an exclusive licensing agreement for Japan with Cytokinetics of the U.
S. for the development of a new treatment for hypertrophic cardiomyopathy.

Under the terms of the agreement, Bayer will conduct a Phase III study in the country on aficamten, a small molecule with "first-in-class potential", with a view to filing a future application for approval.

Cytokinetics, a San Francisco-based biopharmaceutical company, will continue to develop the drug, which is already the subject of a marketing application in the United States, with a European submission expected by the end of the year.

In addition to an upfront payment of 50 million euros, which could rise to 90 million euros if the product is launched commercially, Cytokinetics could receive up to 490 million euros in milestone payments and royalties on sales of the drug.

Hypertrophic cardiomyopathy is a congenital or acquired disease characterized by ventricular hypertrophy and narrowing of the aorta, which can lead to chest pain, syncope and even death in affected patients.

Copyright (c) 2024 CercleFinance.com. All rights reserved.